Sneak Peek of ZEISS Metrology Expert Tips Season 2

The second season of the video series starts in January 2026, but you can discover more about the highlights of Season 2 now.

Bioscience – Groundbreaking Research & Diagnostics: Stockholm (2025)

ZEISS at EMO Hannover 2025

Experience some of the most exciting highlights from our ZEISS product portfolio.

Pharma Outsourcing – Find the Right Partner (2025)

Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

Novo Nordisk tells staff to return to office

At the turn of the year, Novo Nordisk employees will no longer be able to work remotely. According to the company’s new CEO, the move is intended to accelerate ...

15-procentiga tullar på läkemedel – så reagerar branschen

Riktigt illa – men det kunde ha varit ännu värre. Så kan branschens reaktioner på uppgörelsen om USA:s läkemedelstullar mot EU sammanfattas.

Astra Zeneca pauses multi-million investment in the UK

Astra Zeneca has paused a planned investment worth $270 million. It is the latest pharmaceutical company to pull back on its commitments in the UK.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

Canada approves leqembi as global alzheimer’s drug race heats up

Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 15 major markets — one more than its closest rival, Eli Lilly’s Kisunla....

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS 2025 in Copenhagen.

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2025)

Här är topp fem dyraste läkemedlen 2025

Nya avancerade terapiläkemedel når marknaden, men prislapparna är höga. På årets lista över de dyraste läkemedlen i USA finns en gemensam nämnare: alla är gente...

The top five most expensive drugs in 2025

New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Lista: Årets mest framstående medicinska uppfinningar

Den subkutana formen av det svenskutvecklade alzheimerläkemedlet Leqembi lyfts fram när Time presenterar sin årliga lista över de bästa uppfinningarna 2025.

Meet us at Control 2025

Innovations that drive efficiency.

Höjdpunkter från Bioscience Göteborg 2025

En blandning mellan teknik, medicin, terapi och diagnostik. Så beskriver moderator Johan Rockberg vetenskapskonferensen, och sammanfattar några av de viktigaste...

Kanada godkänner Leqembi – racet om alzheimerläkemedel hårdnar

Leqembi får godkännande i Kanada och stärker därmed sitt globala försprång. Läkemedlet är nu godkänt på 15 större marknader – en mer än rivalen Kisunla.

IVDR Reality Check: Are We Moving Fast Enough?

As of February 2025, around 1,500 IVDR certificates have been issued. But if an estimated 18,700 devices still need certification before the 2029 deadline, then...

Wittig – mer än 100 års erfarenhet av pålitlig gaskompression

Wittigs gaskompressorer är oftast det främsta valet vid kompression av biogas, biometan CH4, vätgas H2 och koldioxid CO2. Wittigs lamellkompressorer används mes...

FDA approves first non-opioid pain reliever in over 20 years

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Life science trends 2025 – Neurology

. This part of trend insights on life science 2025 is about neurology.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.